Jeremy Murray

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 484 citations · Full text

Pharmaceutical Chemistry, Tumor Biology, Medicinal Chemistry +19

Optimized arylomycins are a new class of Gram-negative antibiotics

Peter A. Smith, Michael F. T. Koehler, Hany S. Girgis et al. · Nature · 2018 · 348 citations

Antibiotics, Medicine, New Class +6

USP7 small-molecule inhibitors interfere with ubiquitin binding

Lorna Kategaya, Paola Di Lello, Lionel Rougé et al. · Nature · 2017 · 332 citations · Full text

Molecular Docking, Ubiquitin Binding, Drug Target +7

Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling

Cameron L. Noland, Sarah Gierke, Paul D. Schnier et al. · Structure · 2015 · 246 citations · Full text

Hippo Pathway, Systems Biology, Signal Transduction +12

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 212 citations · Full text

Translational Pharmacology, Pre-clinical Pharmacology, Molecular Pharmacology +20